-
2023-504949-31-00
3
2021-12-01
Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) wit
-
2023-508002-20-00
7
2021-10-21
advanced, solid, relapsed tumors / advanced tumors: human lymphomas /
-
2024-510653-10-00
5
2021-06-04
Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years
-
2024-518362-27-00
1
2021-05-18
Patients with recurrent and/or metastatic solid cancer.
-
2023-505924-71-00
4
2021-05-12
Adult patients with metastatic and/or unresectable Non-Small Cell Lung
-
2023-505923-30-00
4
2021-05-11
Patients with hormone-receptor positive (HR+) and human epidermal grow
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2023-508722-99-00
4
2020-11-19
Vulvar cancer
-
2023-508469-34-00
1
2020-10-14
Esophageal cancer
-
2024-515384-62-00
5
2020-10-09
Soft Tissue Sarcoma
-
2024-514542-37-00
9
2020-08-13
Select advanced solid tumors and Non-Small Cell Lung Cancer with MET a
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2024-511904-18-00
10
2020-07-08
Pancreatic adenocarcinoma (PAC)
-
2023-510567-35-00
4
2020-06-10
Advanced / metastatic cancers
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2024-510712-75-00
9
2020-02-12
advanced / metastatic
-
2024-514637-37-00
5
2020-02-11
Patients with bone sarcomas other than chordoma, who have no residual
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-512606-25-00
7
2019-12-20
Advanced Solid Tumors
-
2023-508561-33-00
7
2019-12-12
Newly diagnosed, stage III or IV amenable to surgery, HPV negative, sq
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-511862-35-00
4
2019-07-19
Adults with non-contrast-enhancing diffuse brainstem gliomas with non-
-
2023-508072-11-00
5
2019-06-26
Castration-resistant prostate cancer